期刊文献+

艾塞那肽对2型糖尿病大鼠糖脂代谢和胰岛超微结构的影响 被引量:3

Effects of exenatide on glucose and lipid metabolism and ultrastructure of islet cells in type 2 diabetic rats
在线阅读 下载PDF
导出
摘要 目的研究胰高糖素样肽-1受体激动剂艾塞那肽对2型糖尿病大鼠糖脂代谢和胰岛细胞的影响及其作用机制。方法 健康雄性SD大鼠随机分为正常对照组(C组6只)、正常对照+艾塞那肽处理组(C+E组6只)、糖尿病组(D组5只)以及糖尿病+艾塞那肽处理组(D+E组5只),由高脂饮食加小剂量STZ诱导成2型糖尿病后,D+E组以及C+E组大鼠予艾塞那肽,5μg,腹部皮下注射,1次/d干预;8周后,分别测定各组大鼠体重、FBG、空腹胰岛素(FINS)、稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素敏感指数(ISI)以及血脂谱。同时行透射电子显微镜观察大鼠胰岛组织超微结构改变。结果 D+E组大鼠FBG、FINS、TG、TC、LDL、HOMA-IR水平均明显低于未予干预的D组大鼠(均P<0.05),ISI则显著高于D组大鼠(P<0.05)。超微结构研究,与D组大鼠比较,D+E组大鼠胰岛β细胞数量增加,形态较规则,胞质分泌颗粒增加,颗粒密度较正常;仅见少量线粒体肿胀,结构模糊。内质网结构无明显破坏。结论艾塞那肽能显著改善2型糖尿病大鼠糖脂代谢紊乱,对其残存的胰岛细胞具有明确的保护作用。 Objective To investigate the effects of glucagon- like peptide- 1 agonist exenatide on glucose and lipid metabolism and ultrastructure of islet cel s in type 2 diabetic rats. Methods Twenty- two male SD rats were randomly divided in-to non- diabetic control group (group C, n=6);non- diabetic+exenatide group (group C+E, n=6);diabetic group (group D, n=5) and diabetic+exenatide group (group D+E, n=5). Type 2 diabetes was induced by high- fat diet and low- dose streptozotocin in rats. The rats in C+E group and D+E group were treated with exenatide (5μg/d ) by subcutaneous injection, while the rats in C group and D group were injected with the same volume of normal saline. After 8 weeks, the body weight, fasting blood glucose, insulin, homeoestasis model assessment (HOMA- IR), insulin sensitivity index (ISI) and blood lipid profile were determined in al groups. The ultrastructure of islet cel s was observed with transmission electron microscopy. The one- way ANOVAs fol owed by a Student- Newman- Keuls post hoc test for multiple comparisons were used for statistics. Results Compared with group D, the fasting blood glucose, insulin, triglyceride, total cholesterol, lower density lipoprotein levels, and HOMA- IR were significantly de-creased (al P〈0.05), while ISI significantly increased (P〈0.05) in the D+E group. Electron microscopy observation revealed that exenatide attenuated the swol en mitochondria and endoplasmic reticulum in islet cel s of the diabetic rats. Conclusion The glucagon- like peptide- 1 agonist exenatide can significantly improve glucose and lipid metabolism and protect islet cel s in type 2 diabetic rats.
出处 《浙江医学》 CAS 2015年第5期363-366,共4页 Zhejiang Medical Journal
基金 浙江省中医药优秀青年人才基金项目(2013ZQ004)
关键词 糖尿病 胰高糖素样肽- 1受体激动剂 胰岛细胞 超微结构 Diabetes Glucagon like peptide 1 agonist Islet cel s Ultrastructure
  • 相关文献

参考文献14

  • 1Ferrannini E, Mari A. beta-Cell function in type 2 diabetes [J]. Metabolism, 2014,63(10): 1217-1227.
  • 2陆珣靓,李成江.GLP-1的生理作用及其机制研究进展[J].浙江医学,2011,33(1):137-140. 被引量:6
  • 3Nadkarni P, Chepurny O G, Holz G G. Regulation of glucose homeostasis by G LP- 1 [J]. Prog Mol Biol Transl Sci, 2014,121:23- 65.
  • 4Nachnani J S, Bulchandani D G, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas [J]. Diabetologia, 2010,53(1):153-159.
  • 5Halban P A, Polonsky K S, Bowden D W, et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for pre- vention and treatment[J]. Diabetes Care, 2014,37(6): 1751 - 1758.
  • 6Campos C. Chronic hyperglycemia and glucose toxicity: patholo- gy and clinical sequelae[J]. Postgrad Med, 2012,124(6):90-97.
  • 7Kanda Y, Hashiramoto M, Shimoda M, et al. Dietary restriction preserves the mass and function of pancreatic beta cells via cell kinetic regulation and suppression of oxidative/ER stress in dia- betic mice[J]. J Nutr Biochem, 2014,26(3):219-226.
  • 8Zorov D B, Juhaszova M, Sollott S J. Mitochondrial reactive oxy- gen species(ROS)and ROS-induced ROS release[J]. Physiol Rev, 2014,94(3):909-950.
  • 9Aronson D. Hyperglycemia and the pathobiology of diabetic complications[J]. Adv Cardiol, 2008,45:1 - 16.
  • 10Wiederkehr A, Wollheim C B. Mitochondrial signals drive insulin secretion in the pancreatic beta-cell[J]. Mol Cell Endocrinol, 2012,353(1-2):128-137.

二级参考文献29

  • 1Holst J J,Gromada J.Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans[J].Am J Physiol Endocrinol Metab,2004,287(2):199-206.
  • 2Hjolund K R,Hughes T E,Deacon C F,et al.The dipeptidyl peptidase-4 inhibitor vildagliptin increases portal concentrations of active GLP-1 to a treater extent that the peripheral concentrations[J].Diabetologia,2008,57:A411.
  • 3Nakagawa A,Satake H,Nakabayashi H,et al.Receptor gene expression of glucagon-like peptide-1,but not glucosedependent insulinotropic polypeptide,in rat nodose ganglion cells[J].Auton Neurosci,2004,110(1):36-43.
  • 4Balkan B,Li X.GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms[J].Am J Physiol Regul Integr Comp Phystol,2000 279(4):1449-1454.
  • 5Holst J J.Glucagon-like peptide-1:from extract to agent[J].The Claude Bernard Lecture,2006,49:253-260.
  • 6Wang X,Cahill C M,Pineyro M A,et al.Glucagon-like peptide-1 regulates the beta cell transcription factor,PDX-1,in insulinoma cells[J].Endocrinology,1999,140(10):4904-4907.
  • 7Degn K B,Brock B,Juhl C B,et al.Effect of intravenous infusion of exenatide(synthetic exendin-4) on glucose-dependent insulin secretion and counterregulationduring hypoglycemia[J].Diabetes,2004,53(9):2397-2403.
  • 8Creutafdldt W O,Kleine N,Willms B,et al.Glucagonostatic actions and reduction of fasting hyperglycaemiaby exogenous glucagon-like peptide Ⅰ (7-36) amide in type Ⅰ diabetic patients[J].Diabetes Care,1996,19(6):580-586.
  • 9Naslund E,Bogefors J,Skogar S,et al.GLP-1 slows solid gastric emptying and inhibits insulin,glucagon,and PYY release in humans[J].Am J Physiol,1999,277:R910-916.
  • 10Imeryuz N,Yegen B C,Bozkurt A,et al.Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms[J].Am J Physiol,1997,273:G920-927.

共引文献5

同被引文献30

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部